FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997349871> ?p ?o ?g. }

• W1997349871 endingPage "1030" @default.
• W1997349871 startingPage "1022" @default.
• W1997349871 abstract "Temozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers. Thirty patients with minimal prior chemotherapy were enrolled in this phase I trial to characterize the drug’s safety, pharmacokinetics and anti-tumour activity, as well as to assess how food affects oral bioavailability. To determine dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD), temozolomide 100–250 mg m–2 was administered once daily for 5 days every 28 days. The DLT was thrombocytopenia, and the MTD was 200 mg m–2 day–1. Subsequently, patients received the MTD to study how food affects the oral bioavailability of temozolomide. When given orally once daily for 5 days, temozolomide was well tolerated and produced a non-cumulative, transient myelosuppression. The most common non-haematological toxicities were mild to moderate nausea and vomiting. Clinical activity was observed against several advanced cancers, including malignant glioma and metastatic melanoma. Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax ~1 h) and eliminated (mean t1/2 = 1.8 h). Food produced a slight reduction (9%) in absorption of temozolomide. Temozolomide 200 mg m–2 day–1 for 5 days, every 28 days, is recommended for phase II studies." @default.
• W1997349871 created "2016-06-24" @default.
• W1997349871 creator A5005738281 @default.
• W1997349871 creator A5010851480 @default.
• W1997349871 creator A5015685796 @default.
• W1997349871 creator A5047879448 @default.
• W1997349871 creator A5053304892 @default.
• W1997349871 creator A5056466058 @default.
• W1997349871 creator A5075567012 @default.
• W1997349871 creator A5085697571 @default.
• W1997349871 creator A5085803049 @default.
• W1997349871 date "1999-10-29" @default.
• W1997349871 modified "2023-10-06" @default.
• W1997349871 title "Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies" @default.
• W1997349871 cites W1575812451 @default.
• W1997349871 cites W1576871010 @default.
• W1997349871 cites W1637771339 @default.
• W1997349871 cites W1835101589 @default.
• W1997349871 cites W1861898234 @default.
• W1997349871 cites W1973027090 @default.
• W1997349871 cites W1990739350 @default.
• W1997349871 cites W1993808515 @default.
• W1997349871 cites W2025101604 @default.
• W1997349871 cites W2032064524 @default.
• W1997349871 cites W2039403483 @default.
• W1997349871 cites W2043451385 @default.
• W1997349871 cites W2068220280 @default.
• W1997349871 cites W2079203845 @default.
• W1997349871 cites W2079786467 @default.
• W1997349871 cites W2080850099 @default.
• W1997349871 cites W2109549713 @default.
• W1997349871 cites W2136912434 @default.
• W1997349871 cites W2162277347 @default.
• W1997349871 cites W2308844187 @default.
• W1997349871 doi "https://doi.org/10.1038/sj.bjc.6690802" @default.
• W1997349871 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2362937" @default.
• W1997349871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10576660" @default.
• W1997349871 hasPublicationYear "1999" @default.
• W1997349871 type Work @default.
• W1997349871 sameAs 1997349871 @default.
• W1997349871 citedByCount "187" @default.
• W1997349871 countsByYear W19973498712012 @default.
• W1997349871 countsByYear W19973498712013 @default.
• W1997349871 countsByYear W19973498712014 @default.
• W1997349871 countsByYear W19973498712015 @default.
• W1997349871 countsByYear W19973498712016 @default.
• W1997349871 countsByYear W19973498712017 @default.
• W1997349871 countsByYear W19973498712018 @default.
• W1997349871 countsByYear W19973498712019 @default.
• W1997349871 countsByYear W19973498712020 @default.
• W1997349871 countsByYear W19973498712021 @default.
• W1997349871 countsByYear W19973498712022 @default.
• W1997349871 countsByYear W19973498712023 @default.
• W1997349871 crossrefType "journal-article" @default.
• W1997349871 hasAuthorship W1997349871A5005738281 @default.
• W1997349871 hasAuthorship W1997349871A5010851480 @default.
• W1997349871 hasAuthorship W1997349871A5015685796 @default.
• W1997349871 hasAuthorship W1997349871A5047879448 @default.
• W1997349871 hasAuthorship W1997349871A5053304892 @default.
• W1997349871 hasAuthorship W1997349871A5056466058 @default.
• W1997349871 hasAuthorship W1997349871A5075567012 @default.
• W1997349871 hasAuthorship W1997349871A5085697571 @default.
• W1997349871 hasAuthorship W1997349871A5085803049 @default.
• W1997349871 hasBestOaLocation W19973498711 @default.
• W1997349871 hasConcept C112705442 @default.
• W1997349871 hasConcept C121332964 @default.
• W1997349871 hasConcept C126322002 @default.
• W1997349871 hasConcept C142424586 @default.
• W1997349871 hasConcept C181389837 @default.
• W1997349871 hasConcept C2776694085 @default.
• W1997349871 hasConcept C2777389519 @default.
• W1997349871 hasConcept C2780580376 @default.
• W1997349871 hasConcept C2780852908 @default.
• W1997349871 hasConcept C2780964509 @default.
• W1997349871 hasConcept C31760486 @default.
• W1997349871 hasConcept C71924100 @default.
• W1997349871 hasConcept C87355193 @default.
• W1997349871 hasConcept C90924648 @default.
• W1997349871 hasConcept C98274493 @default.
• W1997349871 hasConceptScore W1997349871C112705442 @default.
• W1997349871 hasConceptScore W1997349871C121332964 @default.
• W1997349871 hasConceptScore W1997349871C126322002 @default.
• W1997349871 hasConceptScore W1997349871C142424586 @default.
• W1997349871 hasConceptScore W1997349871C181389837 @default.
• W1997349871 hasConceptScore W1997349871C2776694085 @default.
• W1997349871 hasConceptScore W1997349871C2777389519 @default.
• W1997349871 hasConceptScore W1997349871C2780580376 @default.
• W1997349871 hasConceptScore W1997349871C2780852908 @default.
• W1997349871 hasConceptScore W1997349871C2780964509 @default.
• W1997349871 hasConceptScore W1997349871C31760486 @default.
• W1997349871 hasConceptScore W1997349871C71924100 @default.
• W1997349871 hasConceptScore W1997349871C87355193 @default.
• W1997349871 hasConceptScore W1997349871C90924648 @default.
• W1997349871 hasConceptScore W1997349871C98274493 @default.
• W1997349871 hasIssue "6" @default.
• W1997349871 hasLocation W19973498711 @default.
• W1997349871 hasLocation W19973498712 @default.
• W1997349871 hasLocation W19973498713 @default.

• next